<SEC-DOCUMENT>0001171843-24-005039.txt : 20240904
<SEC-HEADER>0001171843-24-005039.hdr.sgml : 20240904
<ACCEPTANCE-DATETIME>20240903173220
ACCESSION NUMBER:		0001171843-24-005039
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20240903
FILED AS OF DATE:		20240904
DATE AS OF CHANGE:		20240903

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XORTX Therapeutics Inc.
		CENTRAL INDEX KEY:			0001729214
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40858
		FILM NUMBER:		241275196

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 2400 - 745 THURLOW STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E 0C5
		BUSINESS PHONE:		403-607-2621

	MAIL ADDRESS:	
		STREET 1:		SUITE 2400 - 745 THURLOW STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E 0C5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_090324.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html><head><title></title></head><body style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><div align="center"><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;">&#160;</div></div><p style="font-size: 14pt;" align="center"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong></p><p style="font-size: 14pt; text-transform: uppercase;" align="center"><strong>Form 6-K</strong></p><p style="text-align: center;"><strong></strong></p><p style="text-align: center;"><strong>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 <br />UNDER THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="text-align: left;"><strong></strong><strong>For the month of September 2024</strong></p><p style="text-align: left;"><strong>Commission File Number: 001-40858</strong></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>XORTX Therapeutics Inc.</strong></font></p><p style="text-align: center;"><strong>3710 &#8211; 33rd Street NW, Calgary, Alberta, T2L 2M1</strong></p></div><p>Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.<br />Form 20-F [&#160;X ] &#160;&#160;&#160;&#160;&#160;Form 40-F [&#160;&#160; ]</p><p>&#160;</p><hr style="page-break-after: always;" noshade="noshade" /><p><strong>SIGNATURE</strong></p><p>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="font-family: Times New Roman; font-size: 10pt;" border="0" width="100%" cellspacing="0" cellpadding="0"><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" colspan="2" width="6%"><strong>XORTX Therapeutics Inc.&#160;&#160;&#160;&#160;</strong></td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td colspan="2" width="6%">&#160;(Registrant)</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%">&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%"></td></tr><tr valign="top"><td width="47%">Date: September 3, 2024</td><td width="6%">&#160;</td><td width="6%">By:&#160;</td><td style="text-decoration: underline; text-align: left;" align="center" width="47%">&#160;&#160;&#160;&#160;<em>/s/ Allen Davidoff&#160;&#160;</em>&#160;&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">Name:&#160;</td><td style="text-align: left;" align="center" width="47%">Allen Davidoff</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">Title:&#160;</td><td style="text-align: left;" align="center" width="47%">Chief Executive Officer</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%"></td></tr></table><p><!--On September 3, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. <br /><br />(c) Exhibit 99.1. Press release dated September 3, 2024--><hr style="page-break-after: always;" noshade="noshade" /><p style="text-align: center;"><font style="font-size: 10pt;"><strong>EXHIBIT INDEX</strong></font></p><p style="text-align: center;"><font style="font-size: 10pt;">&#160;</font></p><table style="font-size: 10pt;" border="0" cellspacing="0" cellpadding="0"><tr><td><font style="font-size: 10pt;"><a href="exh_991.htm">99.1</a></font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td><font style="font-size: 10pt;"><a href="exh_991.htm">News Release dated September 3, 2024</a> </font></td></tr></table>&#160;</p></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252" ><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><font style="font-size: 14pt;"><strong>Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders</strong></font></p><p style="text-align: center;"><strong></strong></p><p>
 <p align="justify">CALGARY, Alberta, Sept.  03, 2024  (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("<strong>XORTX</strong>" or the &#8220;<strong>Company</strong>&#8221;) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that leading independent proxy advisory firm Institutional Shareholder Services Inc. (&#8220;ISS&#8221;) has recommended Shareholders vote &#8220;FOR&#8221; all the proposed resolutions at the upcoming Annual and Special Meeting of Shareholders (the &#8220;Meeting&#8221;) to be held on September 12, 2024.<br ></p>  <p align="justify">Leading independent third party proxy advisory firm ISS has recommended that shareholders vote <strong><u>FOR</u></strong> all the proposed resolutions.</p>  <p align="center"><strong>The Board of Directors of XORTX recommends that Shareholders&#160;</strong><strong>vote FOR ALL proposed items</strong></p>  <p align="center">&#160;&#160;&#160;&#160;&#160;<em>Your vote is important no matter how many shares you hold. Please vote today.</em></p>  <p align="center">&#160;&#160;&#160;&#160;&#160;<em>The proxy voting deadline is 10:00 am (Calgary time) on Tuesday, September 10, 2024</em></p>  <p><strong>Meeting Details</strong></p>  <p align="justify">XORTX will hold its meeting on September 12, 2024, at 10:00 am (Calgary Time) at the offices of the Company at 3710 &#8211; 33rd Street NW, Calgary.</p>  <p align="justify">Please visit the Company&#8217;s website complete details and links to all relevant documents ahead of the Meeting at the link below:</p>  <p>https://www.xortx.com/investors/news-events/ir-calendar/detail/7671/annual-and-special-meeting-of-shareholders.</p>  <p><strong>Questions &amp; Voting</strong></p>  <p>If you have questions about the meeting matters or require voting assistance please contact XORTX&#8216;s proxy solicitation agent, Laurel Hill Advisory Group at:</p>  <p>North American Toll Free: 1-877-452-7184 (1-416-304-0211 outside North America)<br >Email: assistance@laurelhill.com</p>  <p><strong>About XORTX Therapeutics Inc.</strong></p>  <p align="justify">XORTX is a pharmaceutical company with two clinically advanced products in development: 1) our lead, XRx-008 program for ADPKD; and 2) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection. In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX is available at www.xortx.com.</p> <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td class="hugin" style="max-width:50%; width:50%; min-width:50%;">For more information, please contact:</td><td class="hugin" style="max-width:50%; width:50%; min-width:50%;">&#160;</td></tr><tr><td class="hugin">&#160;</td><td class="hugin">&#160;</td></tr><tr><td class="hugin">Allen Davidoff, CEO</td><td class="hugin">Nick Rigopulos, Director of Communications</td></tr><tr><td class="hugin">adavidoff@xortx.com or +1 403 455 7727</td><td class="hugin">nick@alpineequityadv.com or +1 617 901 0785</td></tr><tr><td class="hugin">&#160;</td><td class="hugin">&#160;</td></tr><tr><td class="hugin">Kim Golodetz, LHA Investor Relations</td><td class="hugin">&#160;</td></tr><tr><td class="hugin">kgolodetz@lhai.com or +1 212 838 3777</td><td class="hugin">&#160;</td></tr></table> <p align="justify"><em><br >Neither the TSX Venture Exchange nor Nasdaq has approved or disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. </em></p>  <p align="justify"><strong>Forward Looking Statements</strong></p>  <p align="justify">This press release contains express or implied forward-looking statements pursuant to applicable securities laws. These forward-looking statements include, but are not limited to, the Company's beliefs, plans, goals, objectives, expectations, assumptions, estimates, intentions, future performance, other statements that are not historical facts and statements identified by words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or words of similar meaning. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks, uncertainties, and other factors include, but are not limited to, our ability to obtain additional financing; the accuracy of our estimates regarding expenses, future revenues and capital requirements; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and, our ability to obtain and maintain intellectual property protection for our product candidates. Except as otherwise required by applicable law and stock exchange rules, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading &#8220;Risk Factors&#8221; in XORTX&#8217;s Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.</p> </p><p ></p></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
